Skip to content

EBIT at other companies

Altimmune logo
AltimmuneALT
-$24.24M-11.1%
Viking Therapeutics logo
Viking TherapeuticsVKTX
-$164.13M-196%
Wave Life Sciences logo
Wave Life SciencesWVE
-$31.3M+37.2%
Prime Medicine logo
Prime MedicinePRME
-$50.65M+3.3%
Eli Lilly logo
Eli LillyLLY
Amgen logo
AmgenAMGN

Other financials

Income statement

See full
Revenue-
Gross profit$130.0K
Operating income-$6.8M-4.0%
Net income-$6.8M-7.6%
EPS (diluted)-$0.08+27.3%

Balance sheet

See full
Cash & equivalents$19.0M+57.7%
Total debt$18.3M-3.5%
Total equity$19.1M+64.2%
Total assets$42.4M+19.5%

Cash flow

See full
Operating cash flow-$6.2M-20.0%
CapEx$3.0K-40.0%
Free cash flow-$6.2M-19.9%

Valuation

See full
Market cap$106.93M+40.0%
Enterprise value$106.17M+19.3%

Profitability

See full
Gross margin36.3%
Operating margin-1,004.9%
Net margin-994.1%
FCF margin-832.3%

Returns & leverage

See full
Return on equity-176.4%+175pp
Debt / equity-0.7×
Current ratio3.2×+0.8×

Where this comes from

Calculated from Vivani Medical’s reported figures.

The official record: Vivani Medical’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vivani Medical's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vivani Medical's EBIT?
Vivani Medical (VANI) reported EBIT of -$6.82M in Q1 2026.
How has Vivani Medical's EBIT changed year-over-year?
Vivani Medical's EBIT decreased by 4.0% year-over-year, from -$6.56M to -$6.82M.
What is the long-term trend for Vivani Medical's EBIT?
Over 4 years (2021 to 2025), Vivani Medical's EBIT has grown at a 29.1% compound annual growth rate (CAGR), from -$9.92M to -$27.55M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.